Therapeutic Antibody Lead Discovery
Find the tools you need to select the most promising
lead candidates.
Therapeutic antibody lead discovery involves the selection of antibody candidates for targeted therapies. After a specific target has been identified, antibodies are produced using the target molecule as an antigen. Antibodies can be generated using methods including hybridoma technology, B cell cloning, and phage display. Antibodies are then purified and screened for their ability to bind antigen. Selected antibodies are further characterized to determine their specificity, affinity, stability, and pharmacokinetic properties. We provide numerous platforms and reagents to support the lead discovery process, from monoclonal antibody generation to isolation, selection, and lead optimization.
Lead Discovery for Monoclonal Antibodies
TIME AND MONEY
Monoclonal antibody production is one of the most time-consuming and laborious phases in discovery. Recent advances in B cell cloning and phage display have revolutionized antibody library generation, reducing cost and accelerating lead discovery timelines.
Related Categories
We offer a broad range of chromatography tools for protein purification.
Tools for gene editing, cloning, PCR, and protein expression and detection.
Human primary cells, normal and disease state PBMCs, and immune cells.
Human iPSC-derived and patient-derived organoids for advanced cell culture.
Promoting natural, multidimensional growth for more relevant in vitro models.
Hydrogels, organoids, ULA plates, microwell plates, and other cultureware.
Related Articles
- Hybridoma Fusion Partner Cell Lines
Choose from dozens of options to find the optimal fusion partner and increase the efficiency of hybridoma growth and antibody synthesis.
- Cryopreserved PBMCs Retain Function and Phenotype
Frozen peripheral blood mononuclear cells offer many advantages over fresh PBMCs, enabling researchers to plan their experiments ahead of time with ready-to-use cells that can be stored in the freezer until needed.
- Gastrointestinal Organoid Biobank
Patient derived organoids (PDOs) can be used as in vitro 3D cell models, preserving original tissue physiology and molecular pathology for clinical relevance.
- Lung Cancer Organoid Biobank
Lung patient derived organoids (PDOs) have been shown to be a reliable model for lung cancer studies, and can also predict patient clinical responses to therapeutics.
- A Highly Sensitive IFN-γ ELISpot Assay to Quantify Cellular Immune Responses to Previous Viral Infection
This study presents an example of a typical ELISpot assay for quantifying the number of pre-existing, antigen-reactive T cells from peripheral blood mononuclear cell (PBMC) samples obtained from donors previously infected with cytomegalovirus (CMV).
- The ELISpot Assay Enables Functional Analysis of Cellular Immunology
Recent improvements to the design of multiwell microplates, including use of membranes with reduced background fluorescence, have bolstered the widespread application of ELISpot assays.
Related Video
Explore our Products & Services
To continue reading please sign in or create an account.
Don't Have An Account?